<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> 1 (NF1) gene product, neurofibromin, contains a GTPase-activating protein (GAP)-related domain, or NF1 GRD, that is able to down-regulate p21ras by stimulating its intrinsic GTPase </plain></SENT>
<SENT sid="1" pm="."><plain>Since p21ras.<z:chebi fb="11" ids="15996">GTP</z:chebi> is a major regulator of growth and differentiation, mutant neurofibromins resulting from <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in the NF1 gene might interfere with ras signaling pathways and contribute to the development of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We describe an amino acid substitution in the NF1 GRD, altering Lys-1423, that has occurred in three <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types: <z:mp ids='MP_0009314'>colon adenocarcinoma</z:mp>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and anaplastic <z:hpo ids='HP_0009592'>astrocytoma</z:hpo>, and in one family with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> 1 </plain></SENT>
<SENT sid="3" pm="."><plain>The GAP activity of the mutant NF1 GRD is 200- to 400-fold lower than that of <z:mp ids='MP_0002169'>wild type</z:mp>, whereas binding affinity is unaffected </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, germline mutations in NF1 that cause <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> 1 can also occur in somatic cells and contribute to the development of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> not associated with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> 1 </plain></SENT>
</text></document>